Boardroom Alpha
Boardroom Alpha
ABBV · Additional Proxy Materials (DEFA14A) · Filed March 23, 2026

Abbvie Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 23, 2026
Ticker
ABBV
Accession
0001104659-26-033391
Boardroom Alpha · Filing insights

AbbVie's board urges For items 1-4 and Against item 5 on the 2026 proxy; no contest.

About Abbvie Inc
Market cap
$380.6B
1Y TSR
+16.0%
3Y TSR
+19.9%
Board grade
B
Sector
Healthcare
CEO
Robert A Michael
Last annual meeting: May 8, 2026 · View full Abbvie Inc profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.     )

Filed by the Registrant  x

 

Filed by a Party other than the Registrant  o

 

Check the appropriate box:

o

Preliminary Proxy Statement

o

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

o

Definitive Proxy Statement

x

Definitive Additional Materials

o

Soliciting Material under §240.14a-12

 

AbbVie Inc.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

x

No fee required.

o

Fee paid previously with preliminary materials.

o

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11


GRAPHIC

Your Vote Counts! ABBVIE INC. 2026 Annual Meeting For holders as of March 9, 2026 Vote by May 7, 2026 11:59 PM ET. For shares held in a Plan, vote by May 5, 2026 11:59 PM ET. You invested in ABBVIE INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 8, 2026. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # ABBVIE INC. 1 NORTH WAUKEGAN ROAD NORTH CHICAGO, IL 60064 V83855-P47041 Vote Virtually at the Meeting* May 8, 2026 9:00 AM CT Virtually at: www.virtualshareholdermeeting.com/ABBV2026 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote This is only an overview of the more complete proxy materials, which contain important information. View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 24, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

GRAPHIC

Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V83856-P47041 1. Election of Class II Directors Nominees: 1a. Jennifer L. Davis For 1b. Melody B. Meyer For 1c. Robert A. Michael For 1d. Frederick H. Waddell For 2. Ratification of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026 For 3. Say on Pay – An advisory vote on the approval of executive compensation For 4. Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting For 5. Stockholder Proposal – to Adopt a Policy to Require an Independent Chair Against

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Abbvie Inc (ABBV)

Reference

Frequently asked questions

When did Abbvie Inc file this DEFA14A?
Abbvie Inc (ABBV) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 23, 2026. The accession number assigned by EDGAR is 0001104659-26-033391.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
AbbVie's board urges For items 1-4 and Against item 5 on the 2026 proxy; no contest. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Abbvie Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Abbvie Inc has filed under CIK 1551152, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer